Alexion Pharma Canada

Bill C-64: An Act respecting pharmacare, with a particular focus on access to medicines and rare disease and orphan drug policies. Engagement with officials on issues related to the National Strategy for Rare Disease Drugs, and other policies or programs related to rare diseases. Regulatory amendments and/or guidelines and/or policies related to the Food and Drugs Act and Health Canada review of drugs for rare diseases. Guidelines, policies and programs related to regulatory and reporting functions of the Patented Medicine Prices Review Board. Innovation, Science and Economic Development Canada regarding the Innovation and Skills Agenda and other government policies and programs related to incentivizing research and development activities in Canada, including the Biomanufacturing and Life Sciences Strategy. Federal programs and budgetary initiatives related to the Federal-Provincial-Territorial funding arrangements regarding pharmaceuticals including addressing any health technology assessment-related or other policy discussions that might involve Health Canada and its ongoing relationship with Canada's Drug Agency and/or other pan-Canadian health organizations. Federally-funded public drug plans, with respect to reimbursement for drug products for federal plan beneficiaries.

Guidelines, policies and programs related to regulatory and reporting functions of the Patented Medicine Prices Review Board. Federal programs and budgetary initiatives related to the Federal-Provincial-Territorial funding arrangements regarding pharmaceuticals including any health technology assessment-related or other policy discussions that might involve Health Canada and its ongoing relationship with Canada's Drug Agency and/or other pan-Canadian health organizations. Engagement with federal officials regarding Innovation, Science and Economic Development Canada’s Biomanufacturing and Life Sciences Strategy and other government policies and programs related to incentivizing research and development activities in Canada. Canada’s Innovation and Skills Plan, led by Innovation, Science and Economic Development Canada, specifically aspects related to the pharmaceutical and life sciences sector, including intellectual property protection and attraction of investments in research and development.

Engagement with officials on issues related to the National Strategy for Rare Disease Drugs, and other policies or programs related to rare diseases. Regulatory amendments and/or guidelines and/or policies related to the Food and Drugs Act and Health Canada review of drugs for rare diseases. Guidelines, policies and programs related to regulatory and reporting functions of the Patented Medicine Prices Review Board. Innovation, Science and Economic Development Canada regarding the Innovation and Skills Agenda and other government policies and programs related to incentivizing research and development activities in Canada, including the Biomanufacturing and Life Sciences Strategy. Federal programs and budgetary initiatives related to the Federal-Provincial-Territorial funding arrangements regarding pharmaceuticals including addressing any health technology assessment-related or other policy discussions that might involve Health Canada and its ongoing relationship with Canada's Drug Agency and/or other pan-Canadian health organizations. Federally-funded public drug plans, with respect to reimbursement for drug products for federal plan beneficiaries.